

[Date]

[Patient\_First\_Name] [Patient\_Last\_Name]  
[Patient\_Primary\_Address\_2]  
[Patient\_Primary\_Address\_1]  
[Patient\_Primary\_City], «Patient\_State» «Patient\_ZIP»

Dear [Patient\_First\_Name] [Patient\_Last\_Name]:

When enrolling in the LEMTRADA REMS Program, you and your doctor agreed that you will participate in monthly laboratory monitoring for 4 years after your last infusion to monitor for possible side effects.

The lab tests, which are required every 30 days, are important to identify side effects like autoimmune conditions. Please make sure to continue to schedule and go to your monthly lab appointments.

It is also important that you look for symptoms of these side effects by doing your own symptom self-checks, as described in *What You Need to Know About LEMTRADA Treatment: A Patient Guide* that your doctor gave you before you started your LEMTRADA treatment.

As part of the program, you are receiving these monthly reminders for your lab tests. For your convenience, the program offers options on how you can receive your monthly reminders:

- > By mail
- > By phone
- > By email

If you wish to change the way you receive these reminders, please call the LEMTRADA REMS Program at 1-855-676-6326.

If you have questions about LEMTRADA or your monthly lab monitoring, please call the LEMTRADA REMS Program at 1-855-676-6326, Monday through Friday, 8:30 am to 8:00 pm ET. In addition, please contact the LEMTRADA REMS Program if your contact information has changed.

Sincerely,

LEMTRADA REMS Program

**genzyme**  
A SANOFI COMPANY

LEMTRADA and Genzyme are registered trademarks of Genzyme Corporation.  
©2015 Genzyme Corporation, a Sanofi company. All rights reserved. US.MS.LEM.14.10.008-v2

**LEMTRADA**<sup>®</sup>  
alemtuzumab<sup>12mg</sup>  
iv